Latest Oncology News

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

November 30th 2021

Kristi Rosa

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

November 30th 2021

Courtney Marabella

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

November 30th 2021

Gina Mauro

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

November 30th 2021

Jessica Hergert

The Japan Pharmaceuticals and Medical Devices Agency has approved the PD-1 inhibitor pembrolizumab for frontline use in combination with 5-fluorouracil plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma.

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

November 30th 2021

Caroline Seymour

The combination of pembrolizumab and axitinib demonstrated comparable activity and safety vs sunitinib in Japanese patients vs the global population of patients with newly diagnosed metastatic renal cell carcinoma enrolled in the phase 3 KEYNOTE-426 trial.

Latest Oncology Videos

All Oncology News

Mirvetuximab Soravtansine Shows Promising Topline Results in FRα-High, Platinum-Resistant Ovarian Cancer

November 30th 2021

Courtney Marabella

The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab.

FDA Grants Priority Review to Olaparib for BRCA+, High-Risk Early Breast Cancer

November 30th 2021

Caroline Seymour

The FDA has granted a priority review designation to a supplemental new drug application for the use of olaparib as adjuvant therapy in patients with BRCA-mutated, high-risk, HER2-negative early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research Forward

November 30th 2021

DONALD J. JOHANN JR, MD, MSC

The use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.

Abiraterone/Docetaxel Combo Associated With Improved QOL Vs Docetaxel in mHSPC

November 30th 2021

Jessica Hergert

Patients with locally advanced or metastatic hormone-sensitive prostate cancer who received docetaxel and abiraterone acetate plus prednisone or prednisolone and standard of care androgen deprivation therapy had superior patient-reported quality of life compared with patients who received docetaxel plus ADT, although the improvement narrowly missed the predefined value for clinical significance.

Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer

November 29th 2021

Maggie Tibbitt

Howard S. Hochster, MD, discusses molecular markers for patients with gastric cancer, using gene expression profiles as biomarkers, and choosing between anti–PD-1 and anti–CTLA-4 agents.

Florida Cancer Specialists & Research Institute Celebrates Opening of New State-of-the-Art Cancer Center in Bradenton

November 29th 2021

Florida Cancer Specialists & Research Institute held a ribbon-cutting ceremony to mark the opening of its new state-of-the-art cancer center in Manatee County.

Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma

November 29th 2021

OncLive Staff

Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.

FDA Approves Pafolacianine Sodium Injection for Ovarian Cancer Identification

November 29th 2021

Gina Mauro

The FDA has approved pafolacianine sodium injection (Cytalux) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

Pembrolizumab/Lenvatinib Approved in Europe for Frontline RCC

November 29th 2021

Gina Mauro

The European Commission has approved the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced renal cell carcinoma.

European Commission Approves Pembrolizumab/Lenvatinib for Advanced or Recurrent Endometrial Cancer

November 29th 2021

Gina Mauro

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

CG0070 Plus Pembrolizumab Shows Early Tolerability and Activity in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

November 29th 2021

Caroline Seymour

The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Brittany Lovely

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021

Caroline Seymour

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Novel Chemoprotective Therapies Under Investigation

November 29th 2021

Hope S. Rugo, MD

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

Sequencing Therapy in HR+/HER2- MBC

November 29th 2021

Joyce O'Shaughnessy, MD

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

See All News